Vanguard reports 0 shares of Axsome (Schedule 13G/A)
The Vanguard Group filed an amendment to a Schedule 13G reporting its beneficial ownership in Axsome Therapeutics Inc. The filing states 0 shares beneficially owned, representing 0% of the class as reported in the amendment dated 03/13/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed an amendment to a Schedule 13G reporting its beneficial ownership in Axsome Therapeutics Inc. The filing states 0 shares beneficially owned, representing 0% of the class as reported in the amendment dated 03/13/2026.
The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries and business divisions to report ownership separately; the statement clarifies those entities pursue the same investment strategies previously followed.
Insights
Vanguard reports no beneficial ownership after internal disaggregation.
The amendment confirms 0 shares0%03/13/2026, reflecting a reporting change tied to Vanguard's internal realignment effective January 12, 2026. This is an administrative disclosure rather than a trading signal.
Cash‑flow treatment and any trades by disaggregated subsidiaries are not detailed in the excerpt; subsequent filings from the named subsidiaries would show actual holdings if present.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Vanguard report for AXSM ownership in this Schedule 13G/A?
Why does the filing mention an internal realignment dated January 12, 2026?
When was the amendment signed and who signed it?
AI-generated analysis. How Rhea-AI works. Not financial advice.